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ABSTRACT
Splenic marginal zone lymphoma (SMZL) is a malignancy of mature B-cells
that primarily involves the spleen, but can affect peripheral organs as well. Even
though SMZL is overall considered an indolent malignancy, the majority of cases will
eventually progress to be more aggressive. In recent years, the gene expression
profile of SMZL has been characterized in an effort to identify: 1) the etiology of SMZL,
2) biological consequences of SMZL, and 3) putative therapeutic targets. However,
due to the vast heterogeneity of the malignancy, no conclusive target(s) have been
deciphered. However, the role of miRNA in SMZL, much as it has in chronic lymphocytic
leukemia, may serve as a guiding light. As a result, we review the comprehensive
expression profiling in SMZL to-date, as well as describe the miRNA (and potential
mechanistic roles) that may play a role in SMZL transformation, particularly within
the 7q region.

in SMZL development are essential for improving the
diagnostic and prognostic reliability.

INTRODUCTION
Splenic marginal zone lymphoma (SMZL) is a lowgrade, mature B-cell lymphoma, primarily involving the
spleen with variable progression seen in the bone marrow
and peripheral blood [1, 2]. SMZL accounts for less than
2% of all lymphoid malignancies and is responsible for
less than 1% of non-Hodgkin’s lymphoma cases [3–5].
SMZL is considered an indolent B-cell lymphoma as the
median overall survival (OS) for SMZL cases is between
8 and 11 years, but clinical presentations remain very
heterogeneous [6–8]. Most importantly, it is estimated that
70% of SMZL cases will at some point require treatment
for worsening symptoms [2, 9], and approximately
30% of SMZL patients will display a more aggressive
prognosis with potential for progression to more lethal
lymphomas and a decreased overall survival [1, 10–14].
Due to the limited number of available cases as well as
the heterogeneous nature of SMZL, it is very difficult
to differentiate indolent and aggressive SMZL cases,
resulting in treatment inconsistencies and discrepancies
among predicted clinical prognoses. Consequently, further
investigations into the biological mechanism(s) that result
www.oncotarget.com

Etiology of SMZL
In an effort to elucidate the biological mechanisms
of SMZL, research involving gene expression analyses
and chromosomal aberration studies have been conducted.
Specifically, SMZL presents with genomic instability
in approximately 75% of cases, resulting in one of the
highest percentages compared to other B-cell lymphomas,
and accentuating the variable nature of the disease
[15]. This variability offers potential opportunities in
identifying diagnostic and subsequent treatment targets.
Thus far, the most common chromosomal abnormality is
a 7q deletion occurring in 30% to 40% of patients. The
loss of 7q regions is seen much more frequently in SMZL
compared with similar B-cell neoplasms, and thus, it has
been proposed as a primary diagnostic marker [16–19].
The primary region resulting in the loss of heterozygosity
(LOH) has been identified between 7q21 and 7q33, but the
precise chromosomal locations responsible, and resulting
mechanisms, remain unknown [20–22]. Further, the direct
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effects of the 7q deletion on SMZL pathogenesis also
remains controversial.
In addition to the deletion within the 7q region, there
are a plethora of other cytogenetic abnormalities identified
in previous studies. These include various, inconsistent
translocations, gains primarily in 3q, 4q, 5q, 9q, 11q, 12q,
and 20q, and losses occurring in 6q, 8p, 13q, 15q, and
17p [19, 23–27]. The many discoveries of chromosomal
abnormalities have assisted in the identification of
SMZL, but understanding the mechanistic progression
of the disease has still eluded investigators in cytogenetic
investigations.
Along with the challenge posed by the heterogeneity
of chromosomal aberrations, finding patterns among
other biological indicators has proven equally as difficult.
While cytogenetic investigations have been cited for
their importance, it has been suggested that targeting
gene mutations will provide more clinical relevance than
the former [28]. In an effort to identify crucial genetic
abrogates, a number of genetic mutations and deletions
have been investigated for their roles in the NF-κB
pathway, cell communication, apoptosis, metabolism, cell
cycle control, lymphocyte development, and chromosomal
and transcriptional regulation (Table 1).
While each study puts forth potential genetic targets
for unraveling the pathogenesis of SMZL, there are still
wide discrepancies among which targets will be most
fruitful for further investigations. The chromosomal and
genetic abnormalities most commonly annotated, along
with their frequencies seen across SMZL, are provided
in Table 2. Insight into the abnormal genetic landscape
and transcriptional regulation of SMZL has presented a
plethora of candidates for diagnosing and elucidating
SMZL, but similar to the results of cytogenetic studies,
conclusions identified from DNA-level mutations do not
provide transparent explanations for fully deciphering
the biology behind the progression and heterogeneity of
SMZL.
To better understand SMZL, studies into various
regulatory mechanisms should be conducted as an attempt
at explaining the heterogeneity among chromosomal and
genetic aberrations. One mechanism of post-transcriptional
regulation is via epigenetic modifications, primarily being
methylation of DNA promotor sequences. Deregulated
DNA methylation has been implicated in the development
of similar B-cell malignancies [54–58], and hence,
Arribas et al. published a genome-wide DNA-promoter
methylation profiling study in an effort to characterize
the differential patterns within SMZL [59]. A cohort
of patients was identified with significantly increased
promotor methylation, and it was associated with a
decreased OS compared to patients without the increased
methylation profile. Additionally, certain promoter
methylation patterns were identified and shown to affect
the same biological pathways that were implicated in the
genetic studies. While methylation patterns provide one
www.oncotarget.com

option for mechanistic regulation studies, there are other
molecular components worthy of investigation as well in
an effort to improve comprehension of SMZL pathology.

MicroRNAs and B-cell lymphomas
Non-coding RNA molecules are regulatory
biological elements that warrant further investigation due
to their well-established mechanistic impacts and their
relationships with genetic and chromosomal aberrations.
MicroRNAs (miRNAs), a type of non-coding RNA, are 20
to 22 nucleotide post-transcriptional regulators that have
been heavily researched and reported on for their role in
various cancers over the past decade [60–62]. MicroRNAs
function by targeting complementary messenger RNAs
(mRNAs), allowing them to regulate almost any cellular
process that is a result of translation. The idea that
miRNAs could play a role in lymphomagenesis originated
from evidence that the miR-15/16 cluster was frequently
deleted in chronic lymphocytic leukemia (CLL), resulting
in the loss of tumor suppression [63]. Following this
breakthrough, a plethora of studies were conducted to
identify other miRNA in CLL pathogenesis as well as
other lymphomas [64–66]. By exposing the oncogenic
role of miRNA, they became an option for new treatment
targets [67], diagnostic and prognostic markers [68, 69],
and mechanism manipulation candidates [68, 70].
Preliminary studies have been conducted on the
miRNA profile of SMZL, but the role for specific miRNA
on SMZL pathogenesis remains to be discovered. Previous
investigations into miRNA signatures of similar neoplasms
may be informative for deciphering mechanistic impacts of
deregulated miRNA in SMZL. Fortunately, unlike SMZL,
many B-cell lymphomas have had their miRNA profiles
investigated and reviewed extensively. Some miRNAs that
are recurrently deregulated among B-cell lymphomas have
been elucidated due to their role in B-cell development,
migration, or activation [71]. Additional miRNAs also
repeatedly identified in B-cell lymphomas are deregulators
of “hallmark” cancer functions such as increased
proliferation, evasion of suppressors, mortality resistance,
and others [72]. The miRNAs consistently identified across
B-cell lymphoma studies to be abnormally expressed
include: miR-34a, miR-155, the miR-17/92 cluster, miR21, and miR-150, with many more additional markers also
discussed [62, 68, 71–74]. Many of these markers have
also been found to be differentially expressed in SMZL
miRNA profiles, but due to the exhaustive reporting on
these miRNAs in B-cell lymphomas, no further discussion
will be provided in this review regarding their potential
role in lymphomagenesis. Instead, this review will provide
an overview of the unique miRNAs hypothesized to play
a role in SMZL pathogenesis. Furthermore, we propose
why these miRNA targets warrant future investigations
and discuss their oncogenic potential. A summary of all
miRNAs reported to be relevant to the biology of SMZL
is captured in Table 3.
30006
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Table 1: Summary of significantly deregulated genes and their resultant affected pathways in SMZL
Pathway

Deregulated genes

Citation

NF-κB

[6, 28-38, 41]
IKBKB, TNFAIP3 (A20), BIRC3, TRAF3,
MAP3K14, CD40, SYK, BTK, PKCA, REL,
TRAF5, PTPRC, PTPN1, TNFRSF5, LTB,
MYD88, CARD11, FAS, CREBBP, NFKBIZ, KLF2

Cell Communication

MS4A2, SYK, TOSO, SELL, LPXN, PTPRC,
PTPN1, RASSF2, BIRC3, TNFRSF5, TRAF3,
TRAF5, ENPP2, BTK, PDE4B, PLEXINA2,
ARHGAP25, ARHGAP32, MYCBP2, FLNC,
LCP1, CALU

Apoptosis

BIRC3, TNFRSF5, TRAF3, TRAF5, BTK, APAF-1, [30, 36, 39]
XPB

Metabolism

UBD, SYK, E2F5, SP140, PFTK1, LPXN, PTPRC, [30, 33]
PTPN1, TNFRSF5, EIF4B, BTAF1, AMPD3,
POU2AF1, EGR2, ENPP2, BTK, ICSBP1

Cell Cycle Control

CDKN2A, CUL1, TP53, ARID3A, JUN, JUNB,
JUND, FOS, EVI5, TMEM209, ZC3HC1

[27, 28, 33, 36-39, 41, 43]

Lymphocyte Development and
Regulation

NOTCH2, NOTCH1, SPEN, DTX1, SWAP70,
MAML2, BTK, CXCR4, ARID3A, KLF2,
NOTCH3, NOTCH4, PAX5, MAP3K8, IRF5

[27, 28, 33, 34, 36, 37, 39-43]

Chromosomal and Transcriptional
Regulation

[27, 28, 33, 34, 36-38, 40]
MLL2, ARID1A, EP300, CREBBP, SIN3A,
TBL1XR1, GPS2, SMYD1, MLL3, ARID4A,
HIST1H1D, HIST1H1E, HIST1H2BI, HIST1H4H,
SMARCA2, CHD2, BCOR, CBFA2T3, BCL6,
POT1, ILF1

[30, 33, 36, 37, 39, 43]

Table 2: Molecular aberrations most prevalent in SMZL, and the frequency of occurrence in SMZL cases
GENETIC ABNORMALITIES
Gene

Mutation frequency

Citation

~ 40%

[27, 28, 33, 34, 36, 37, 39, 40, 44]

KLF2

20% - 40%

[28, 41, 42]

NF-κB pathway (CARD11, IKBKB,
TNFAIP3, TRAF3, BIRC3, etc.)

35% - 45%

[28, 29, 31, 33, 35-37, 41]

MYD88

10% - 15%

[28, 33-35, 41]

TP53

10% - 20%

[28, 37, 41, 45–47]

NOTCH2

CHROMOSOMAL ABERRATIONS
Location

Incidence

Citation

7q Deletion

30% - 40%

[10, 16, 19-27, 43, 48-53]

3q Gain

10% - 20%

Misc. Gains (6p, 8q, 9q, 12q, 18q)

8% - 18%

Misc. Losses (6q, 8p, 14q, 17p)

8% - 16%

www.oncotarget.com
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Table 3: Characterization of the miRNA expression (and their location) in SMZL, inclusive of all
previously published, relevant studies
miRNA

Location

SMZL expression status

Citation

miR-155

21q21.3

O

[77–79]

miR-451

17q11.2

O, OL

[73, 77]

miR-486

8p11.21

O, OL

[73, 77]

miR-146a

5q33.3

O, OL

[79, 80]

miR-494

14q32.2

O

[79]

miR-34a

1p36.22

O

[78, 79]

miR-193b

16p13.12

O

[78]

miR-100

11q24.1

O

[78]

miR-330

19q13.32

O

[78]

miR-21

17q23.1

O, UL

[77–79]

miR-144

17q11.2

OL

[73]

miR-204

9q21.12

OL

[73]

miR-212

17p13.3

OL

[73]

miR-409-3p

14q32.31

OL

[73]

miR-421

Xq13.2

OL

[73]

miR-432

14q32.2

OL

[73]

miR-487a/487b cluster

14q32.31

OL

[73]

miR-520d

19q13.42

OL

[73]

Xq26.3

OL

[73]

miR-574

4p14

OL

[73]

miR-595

7q36.3

OL

[73]

miR-650

22q11.22

OL

[73]

miR-29a/29b-1 cluster

7q32.3

U

[75–77]

miR-127

14q32.2

U, OL

[73, 77, 78]

miR-139

11q13.4

U, OL

[73, 77]

miR-335

7q32.2

U

[21, 76, 77]

miR-411

14q32.31

U

[77]

miR-593

7q32.1

U

[21, 76]

miR-129-1

7q32.1

U

[21, 76]

miR-139-5p

11q13.4

U

[79]

miR-345

14q32.2

U

[79]

miR-95

4p16.1

U, OL

[73, 79]

miR-138

3p21.32

U

[79]

miR-125a-5p

19q13.41

U

[79]

9q34.3

U, OL

[73, 79]

miR-542-3p

miR-126

(Continued )
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miRNA

Location

SMZL expression status

Citation

miR-146b-5p

10q24.32

U

[79]

miR-223

Xq12

U

[80]

miR-377

14q32.31

U

[78]

miR-27b

9q22.32

U

[78]

miR-145

5q32

U

[78]

miR-376a/376b cluster

14q32.31

U

[78]

miR-381

14q32.31

U

[78]

miR-494

14q32.31

U

[78]

miR-382

14q32.31

U

[78]

miR-154

14q32.31

U

[78]

miR-410

14q32.31

U

[78]

miR-758

14q32.31

U

[78]

miR-485-3p

14q32.31

U

[78]

miR-136

14q32.31

U, OL

[73, 78]

miR-379

14q32.31

U

[78]

miR-338

17q25.3

U

[78]

miR-107

10q23.31

U

[78]

miR-24

9q22.32

U

[78]

miR-328

16q22.1

U

[78]

miR-199a

19p13.2

U

[78]

miR-483

11p15.5

U

[78]

miR-589

7p22.1

U, UL

[78]

miR-182/96/183 cluster

7q32.2

UL

[21, 76]

miR-26b

2q35

UL

[78]

miR-19b

13q31.3

UL

[78]

miR-660

Xp11.22

UL

[78]

miR-448

Xq23

UL

[78]

miR-646

20q12.33

UL

[78]

miR-323

14q32.31

UL

[78]

miR-567

3q13.2

UL

[78]

miR-141

12p13.31

UL

[73]

miR-199b

9q34.11

UL

[73]

miR-200c

12p13.31

UL

[73]

miR-210

11p15.5

UL

[73]

miR-663

20p11.1

UL

[73]

miR-99a

21q21.1

UL

[73]

Abbreviations: O, overexpressed compared to normal spleen; U, under-expressed compared to normal spleen; UL,
underexpressed compared to B-cell lymphomas; OL, over-expressed compared to B-cell lymphomas.
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miRNAs in SMZL

Mechanistic impact of miRNA

The first study to propose a biological effect by
miRNA on SMZL was published by Ruiz-Ballesteros
et al. in 2007 and reported decreased expression levels
of miR-29a and miR-29b-1 [75]. The two miRNA were
chosen for the first study due to their proximity to the
commonly deleted 7q region mentioned above, and miR29a is also known to have the potential to target and
regulate TCL1A, a predicted oncogene in SMZL [30,
81]. Subsequent studies followed, also investigating the
association between miRNA levels and 7q mutational
status. Watkins et al. reported a reduction in the
expression of 7 miRNA located at 7q32, consistent with
the chromosomal report of LOH at that location [21, 76].
This sentinel finding ignited curiosity within the scientific
community regarding the role of miRNA and 7q LOH
and should be further investigated to identify possible
mechanistic connections.
The miRNA landscape of SMZL was also studied
beyond the miRNA located at 7q32. Bouteloup et al.
identified a significant variation in expression of 7
miRNAs when comparing healthy samples to SMZL
samples, with two of the identified miRNA being located
at 7q [77]. Additionally, miR-21 over-expression was
associated with the aggressiveness of SMZL cases in
their study. A report published in 2012 investigated
8 different B-cell lymphomas for specific miRNA
signatures within each respective malignancy [73]. SMZL
was included in this study, finding 26 different miRNAs
to be differentially expressed in SMZL, with 20 being
upregulated and 6 being downregulated in SMZL when
compared to the other B-cell lymphomas. Arribas et al.
conducted a more comprehensive analysis of the miRNA
profile for SMZL, finding over 30 miRNAs differentially
expressed when compared to reactive spleens, with 9
miRNAs differentially expressed from similar B-cell
lymphoma miRNA profiles [78]. Lastly, a study designed
to investigate the SMZL miRNA profile, as well as the
role of Hepatitis-C Virus on SMZL miRNA, determined
a key role for 12 differentially expressed miRNAs in
SMZL [79].
Incredibly, across each of the studies, very few
miRNAs were found to be differentially expressed in
multiple instances (Table 3). The variability among the
miRNA profiles once again demonstrates the heterogeneity
across SMZL, but due to the preliminary nature of the
SMZL miRNA knowledge, as well as the vast regulatory
ability of each miRNA, further investigation into their
role on SMZL pathogenesis holds many opportunities.
The identification of potential candidates for mechanistic
studies is the next step to uncovering how posttranscriptional regulation influences SMZL progression.
Taken together, the following miRNA are proposed
candidates for subsequent studies that should be conducted
in an effort to elucidate the biology of SMZL.

The nearly infinite number of mechanistic roles
performed by miRNA have been well established in
the literature. Sifting through the abundance of the
miRNAs for their role in diseases, however, can prove
tedious. Hence, we took a reductionist approach by
looking at the known role of miRNA in SMZL that are
located within the 7q region and a select few of the
miRNA that target caveolin-1 (CAV1). We listed each of
the miRNA identified to be differentially expressed in
SMZL signatures (Table 3), and we propose 7 of those
miRNAs contain potential to be significant contributors
to SMZL pathogenesis. These miRNAs are categorized
into two different designations in an attempt to delineate
the roles that these pathways may play on this specific
lymphomagenesis (Table 4).
The miRNAs located at the 7q region have been
hypothesized to play a role in SMZL progression, and due
to the frequency of 7q chromosomal abnormalities seen in
SMZL, should be investigated for their role. Hence, the first
categorical designation will be miRNA that are transcribed
within the 7q region. This includes miR-29a/b-1, miR-1291, the miR-183/96/182 polycistron, and miR-335.
The other category corresponds to miRNA that
directly target the mRNA of CAV1, a gene located at 7q31
that has been implicated in similar B-cell lymphomas.
There were 9 miRNAs differentially expressed in previous
studies that target CAV1, and of the 9, this review will
discuss 3 of the miRNAs that could be crucial for
exposing a role for CAV1 in SMZL pathogenesis. These
miRNAs discussed below include: miR-199a, miR-376,
and miR-485. The possibilities for the role of miRNAs in
SMZL are almost limitless, but this review provides an
evidence-based list of 7 miRNAs that could be crucial to
understanding this malignancy.

www.oncotarget.com

miRNA located at 7q
The LOH near the 7q32 chromosomal region is a
disruption unique to few lymphomas, and the loss seen
in up to 40% of SMZL patients is the highest among
B-cell lymphomas. As previously discussed, this unique
aberration is being utilized in diagnostic techniques for
SMZL, but the biological mechanisms behind these
losses are difficult to identify. While some groups
have hypothesized that miRNA could play a role in
this LOH, and others have even looked at the miRNA
expression profiles within the 7q32 region in SMZL
tissues, the mechanistic role for these miRNA remains
to be discovered. The 4 miRNAs below demonstrated
significantly lower expression in SMZL cases against
healthy samples or similar malignancies. This differential
expression was seen across multiple studies in most cases,
and the variable expression’s consequent downstream
regulatory alterations may prove important for SMZL
pathogenesis.
30010
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Table 4: Identification of the miRNA at the 7q region, or those that target the oncogene/tumor suppressor caveolin-1
Category

miRNA

Regulation type

Proposed SMZL
regulation target

Transcribed at 7q

miR-29a/b-1 cluster

Tumor Suppressor

TCL1A

miR-129-1

Tumor Suppressor

BCL2

miR-182/96/183 cluster

Tumor Suppressor or Oncogene

FOXO1

miR-335

Tumor Suppressor

Rb1, BCL-w

miR-199a

Tumor Suppressor

IKKβ, CAV1

miR-376

Tumor Suppressor

IGF1R, CAV1/IGF1R/SRC

miR-485

Tumor Suppressor

CAV1

Target CAV1

The proposed target of regulation within SMZL cells is also described.

miR-29a/b-1 cluster

and upon binding to the TCL1A mRNA it deactivates the
oncogenic properties of the impending protein. TCL1A
is an oncogene that has been shown to enhance cancer
progression via its role in cell survival pathways, and it
is commonly over-expressed in aggressive subtypes of
many cancers. It has been shown that miR-29a acts as an
inhibiting regulator of TCL1A in CLL [88], and as miR29 has a reduction in expression, TCL1A demonstrated the
corresponding increase in expression in those cases. TCL1A
has been shown to have increased expression among
SMZL cases [30], and thus, a similar mechanistic role for
miR-29 in SMZL is not out of the question. As mentioned
above, in SMZL cases with which the 7q32 region is
deleted, miR-29a could also be deleted. It has also been
observed in former studies that miR-29a may be underexpressed in SMZL cases, regardless of 7q mutational
status [75]. This deletion or reduction in expression could
result in a lack of TCL1A silencing, and consequently,
would promote lymphomagenesis due to the down-stream
protein’s increased activation and corresponding effects.
Due to the multifaceted regulatory mechanisms of miR29, multiple cellular processes are disrupted upon its down
regulation, as is seen in SMZL, but specific investigations
into the tumor suppressive mechanisms, like the impact
on TCL1A, are necessary for the exploitation of miR-29 in
treatment and diagnostic opportunities.

The miR-29 family contains a two-member miRNA
cluster located distally to a commonly deleted region of 7q,
7q32. The miRNA family contains four members, miR29a,
miR-29b-1, miR-29b-2, and miR-29c. While the cluster
contains the same seed sequence, resulting in many of the
same targets and regulations, only miR-29a and miR-29b-1
are located on 7q. miR-29 is commonly under-expressed in
SMZL spleens when compared with healthy tissues. This
decrease of expression is consistent with the expression
seen in similar B-cell neoplasms, CLL and mantle cell
lymphoma (MCL), as well as many other malignancies
[61, 67, 82–85]. The variable expression of miR-29 has
been viewed with such importance that utilization in
diagnostic, and more importantly prognostic, lymphoma
designations have been proposed [86]. The regulatory
role of miR-29 has been implicated in immune regulation,
cell proliferation, differentiation and apoptosis pathways,
metastatic interference, and even epigenetic modulation
[87]. Due to the myriad of regulatory mechanisms and
variable malignancies affected, miR-29 acts as a tumor
suppressor in some situations while displaying oncogenic
tendencies in others. The replicated under-expression of
miR-29 seen in SMZL is consistent with miR-29 levels
observed in similar B-cell malignancies, indicating that
miR-29 primarily is acting as a tumor suppressor in
SMZL. Further, in situations of LOH at or near the 7q32
region, there could be complete loss of miR-29 transcripts
resulting in possible loss of its tumor suppressive
activity and a much more aggressive progression of the
malignancy. Further studies are necessary to find the
precise mechanistic role of 7q32 status on miR-29 and the
overall impacts on SMZL progression.
Due to the established research into the role of miR29 in lymphomas similar to SMZL, the hypothesized
mechanistic investigations have promising directionality.
A primary target of miR-29a is the mRNA of TCL1A,
www.oncotarget.com

miR-129-1
The miR-129 family is composed of miR-129-1 and
miR-129-2, with the former being located at 7q32 within
the region most commonly deleted in SMZL presentations.
The two miRNA have almost identical seed sequences,
resulting in similar functionalities. miR-129 has been
primarily identified for its tumor suppressive role in various
tumorigeneses, but oncogenic properties of the miRNA have
been discovered as well. miR-129-1 was shown to have
repressed expression of in SMZL. Thus, tumor suppression
30011
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is most likely the route of regulation for this specific
malady. Other cancers have also been found to display
under-expression of miR-129, with a plethora of proposed
mechanistic explanations from cell proliferation, cell cycle,
apoptotic, metastatic, and autophagy pathway regulations
[89]. Karaayvaz et al. investigated the regulation by miR129 as a tumor suppressor, finding that through direct
targeting of B-cell lymphoma 2 (BCL2), miR-129 induces
apoptotic mechanisms and inhibits cell proliferation via cellcycle arrest in colorectal cancer cells [90]. Consequently,
upon decreased expression of miR-129, each of the
tumor suppressive mechanisms are also stifled. A similar
situation may occur in SMZL, as miR-129 shows decreased
expression compared with healthy samples. Further, BCL2
has been found to be over-expressed in SMZL signatures
[78], providing additional evidence for the practicality of
the miR-129 regulatory impact. Investigations into the role
of miR-129-1 on SMZL pathogenesis and 7q LOH may
prove beneficial based on reported information mentioned
above, and thus, the mechanistic understanding of miR-129
related to SMZL should be improved.

regardless, the under-expression of the entire miR-183
cluster seen in SMZL indicate it should be assessed for its
possible mechanistic role in the 7q deletion.
A variety of malignancies have been investigated
for connections to the aberrant role of miR-183 cluster
members on carcinogenesis, but conflicting mechanistic
actions in varying tissues and malignancies make this
evaluation inconsistent. The cluster is commonly overexpressed in many solid tumors, but there has also
been significant under-expression of the cluster in
other malignancies [94]. Even among hematological
malignancies expression is variable. MCL cases present
with an increased miR-182 expression [95], but CLL cases
showed a p53 regulated decrease in miR-182 expression
[73, 96]. Mechanistic relationships between miR-183
cluster members have stretched to many pathways and
functions. There has been regulation in cell proliferation,
cell apoptosis, cell migration, immune signaling, and
DNA repair mechanisms, indicating the wide carcinogenic
outreach of the cluster [97]. Connections to sonic
hedgehog signaling pathways, Pro-apoptotic Programmed
Cell Death (PDCD) family regulation, and regulation
of Forkhead Box O (FOXO) subfamily signaling, just
to name a few, have been published for explanations of
the role the miR-183 cluster, or one of its’ members, has
on various tumorigenesis processes [95, 98–109]. With
such an impactful list of vetted carcinogenic targets,
studies establishing the miR-183 cluster expression
profile in SMZL against healthy/control tissues, and
further investigation into the role of the cluster on SMZL
pathogenesis, could renders vital for understanding the
possible function of 7q LOH in SMZL overall progression.

miR-182/96/183 cluster
The miRNA polycistron consisting of miR-182,
miR-96, and miR-183 is considered a cluster due to the
miRNAs’ proximity to one another. The miR-183 cluster
is located at 7q32, and the miRNAs possess similar seed
sequences, resulting in many shared functionalities. These
miRNAs are typically seen over-expressed in various
cancers, but under-expression has also been observed,
demonstrating the dual tumor-suppressive and oncogenic
role of the polycistron. More specifically, an increased
expression of miR-183 was reported in lung cancer
tissues [91], but in a separate study, miR-183 was found
to have decreased expression in the peripheral blood of
lung cancer cases [92], indicating miR-183 is utilized for
contradictory mechanistic interactions in hematological
and tissue malignancies. As for previously published
miRNA data in SMZL, the miR-183 cluster has been
shown to be under-expressed when compared to similar
B-cell lymphoma samples [76]. The expression values
when compared to control samples were unavailable,
though. Thus, the under-expression seen in SMZL could be
the result of an increase in tumor suppressive properties,
or it could be an indication for a reduction in oncogenic
effects compared to the B-cell lymphoma counterparts.
A polymorphic mutation in approximately one quarter of
SMZL cases has also been found at the region containing
miR-182, indicating possible loss of function in some
SMZL cases [76], but it has also been shown that the
polymorphism can be found among healthy populations at
an only slightly lower occurrence bringing into question
its carcinogenicity [93]. This alteration in miR-182
expression should first be investigated for the in-question
dependence to the aforementioned polymorphism, but
www.oncotarget.com

miR-335
The final miRNA of interest located within the 7q
region is miR-335. Similar to the other miRNA of interest,
miR-335 was significantly under expressed in SMZL
samples when compared to healthy controls. Research
on miR-335 has been done primarily on solid tumor
malignancies but the mechanistic conclusions in studies
have the potential to be translated further [110]. miR335 has been discussed for its role as an oncogene, but
it has contrarily been found to act as a tumor suppressor
in other malignancies. Many of the cancers displaying an
under-expression of miR-335, like SMZL, point to tumor
suppressive mechanisms as its role in carcinogenesis.
One mechanism of action with far-reaching impacts
demonstrated the role of miR-335 in p53 regulation.
Scarola et al. found that miR-335 targets and represses
retinoblastoma 1 (RB1) resulting in the up-regulation of
p53 [111], but p53 pathway activation results in further
up-regulation of miR-335, hence triggering a positive
feedback loop. Thus, in a malignancy like SMZL when
miR-335 is under-expressed, or in a case of 7q deletion
possibly eliminating the coding regions for miR30012
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involving CAV1 resulted in malignant transformations
[114, 115]. When CAV1 is coupled with an oncogene,
CAV1 knockout mice appear more prone to progress to
aggressive forms of cancers than in mice without the
CAV1 knockout [116]. This impact could prove crucial for
deciphering SMZL within an in vivo model and hence has
been recently proposed [117]. The fragility and importance
of the 7q region in SMZL almost certainly implicates
CAV1 as a significant player in the disease etiology due to
its crucial chromosomal location. Thus, the mechanisms
and regulatory pathways extrapolating the role of CAV1
in SMZL pathogenesis are worthy of further investigation.
There have been discrepancies among reported
results regarding CAV1 status in SMZL cases. RuizBallesteros et al. showed decreased expression of CAV1
[30], but Watkins et al. found no differential regulation of
CAV1 in SMZL samples [21]. These inconsistencies may
be a result of additional molecular regulators and their
impacts. There are 9 miRNAs reported to be aberrantly
expressed in the SMZL profile, that have the ability to
target CAV1, and thus, it would be no surprise if miRNAs
regulation on CAV1 may be the culprit responsible for these
discrepancies. Further, CAV1 expression has been reported
to be independent of 7q mutation status also supporting the
idea that regulatory mechanisms beyond chromosomal loss
are almost certainly at work. CAV1 has been shown to be
a crucial piece in immune functioning and dysregulation
in malignancies similar to SMZL, and in order to decipher
the role of CAV1 on SMZL, in cases of 7q LOH or in cases
with 7q intact, miRNA regulation should be investigated
for their impact. There are 3 miRNAs (miR-199a, miR376 cluster, and miR-485) that will be discussed next that
present viable options for CAV1 regulation and, in turn,
impact SMZL pathogenesis (Figure 1).

335 rendering it almost nonexistent, there is no down
regulation of RB1 and no downstream activation of p53,
resulting in a huge decrease in the wide-spread tumor
suppression. Additionally, TP53 deletions and mutations
have been shown in 15% - 25% of SMZL cases [27,
28, 38, 47], which would also result in disruption of the
aforementioned positive feedback loop. Hence, this would
provide an additional explanation for the decrease in miR335 expression. Further investigations into this mechanistic
relationship may prove crucial for understanding miR-335
as well as TP53 functioning in SMZL.
In other work, miR-335 has been shown to
regulate BCL-w, a member of the BCL-2 protein family,
suppressing its role in cell proliferation pathways,
resulting in apoptosis of tumor cells [112, 113]. Again,
as miR-335 is acting as a tumor suppressor, its underexpression would result in less suppression of BCL-W
allowing the tumor cells to proliferate much easier
promoting their survival. Either of the aforementioned
mechanisms could prove helpful in understanding SMZL,
as p53 is a universal tumor suppressor that impacts all
malignancies, and the B-cell lymphoma protein family is
extremely homogeneous and miR-335 targeting of other
BCL homologues should not be overlooked.

miRNA targeting CAV1 in SMZL
The LOH at 7q in SMZL has not been fully
elucidated due to the many regulatory mechanisms that
are possibly responsible or work in conjunction to impose
the aberration. The fragile site FRA7G overlaps with part
of the 7q region commonly deleted in SMZL, and within
that site, at 7q31.2 to be exact, the tumor suppressor and
oncogene, CAV1, resides. Therein other instances of LOH

Figure 1: Graphical representation of affected region on 7q. The predominantly affected region of chromosome 7 frequently
mutated or lost in splenic marginal zone lymphoma is depicted, inclusive of the miRNA within this region that target CAV1.
www.oncotarget.com
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miR-199a

understanding of miR-376 remains unknown. miR-376 has
been shown to impact cancer progression via cell cycle
progression, cell migration and invasion, and autophagy
[134–136]. One mechanism of tumor suppression is the
direct regulation of IGF1R by miR-376a and miR-376c,
resulting in decreased migration and proliferation [134].
Thus, upon reduction of miR-376a expression, as is seen
in SMZL, IGF1R becomes fully activated, promoting
tumor progression. Additionally, IGF1R forms a complex
with CAV1 and SRC in order to induce anti-apoptotic
mechanisms [137]. When inhibition of CAV1 or IGF1R
was applied, it corrupted the complex allowing apoptotic
molecules to resume mitigating tumor development. This
identifies another route that miR-376 may serve as a
tumor suppressor, as it would be able to directly target and
suppress CAV1, IGF1R, or both, to disrupt their oncogenic
mission. Hence, the decrease in miR-376 in SMZL would
limit the capacity for these tumor suppressive functions.
Arribas et al. hypothesized additional predicted
targets of miR-376 that have been shown to act in
tumorigenesis: CD44, MUM1, DLEU1, IL2RA, IL7,
IRTA4, and FOXP1 [78], all of which could potentially
be upregulated in SMZL. Upregulation of FOXP1, for
example, has been demonstrated in SMZL [78]. It is
similarly upregulated in DLBCL signatures, resulting in
increased oncogenic activity [138]. This upregulation of
FOXP1 and subsequent increase in malignant activity
would be consistent with a decrease in miR-376 expression,
and thus, this relationship should be further explored.
Finally, miR-376 has been shown to undergo RNA editing,
resulting in altered mRNA targets, in germinal center based
B-cell lymphomas [139]. This alteration in targets can
result in a multitude of aberrant regulations, possibly even
becoming carcinogenic. And, while the cellular origin of
SMZL is still controversial, it’s plausible that RNA editing
within the miR-376 could assist in tracking etiology in a
subset of cases. Each of the aforementioned mechanisms
present the capability to contribute to SMZL pathogenesis
understanding the impact of miR-376 on SMZL and other
malignancies should be pursued.

The decreased expression of miR-199a seen in
SMZL is consistent with previously published literature.
In studies to this point, miR-199a has demonstrated
tumor suppressive properties, and hence, has been
under-expressed in many of the malignancies being
investigated. Due to its importance as a tumor suppressor
it has been studied for its prognostic significance and
potential as a treatment target in solid and hematological
malignancies [118]. Many studies have demonstrated
the multifaceted, tumor suppressive properties of miR199a. The decreased expression of miR-199a induces an
increase in IKKβ activity, further stimulating the NF-κB
pathway, which results in an enhanced tumor environment
and chemoresistance [119–121]. The proposed tumor
suppressive mechanisms of miR-199a have also
included downregulation of proto-oncogenes and their
corresponding pathways [122], as well as regulation
of mammalian target of rapamycin, cell migration, and
apoptotic pathways [118]. In the malignancy most similar
to SMZL, diffuse large B-cell lymphoma (DLBCL), the
increased expression of miR-199a among patient cohorts
has corresponded to a more favorable progression free
survival and OS [118, 123].
While pathway regulation is important for
elucidating the role of miR-199a, in order to exploit miR199a for more treatment and prognostic options precise
mechanistic understanding must be improved. There
has been research into the mechanistic relationship that
miR-199a and the tumor suppressor and oncogene CAV1
may have. miR199a has been shown to directly target
CAV1 and, in turn, affect the resulting mechanisms in
which CAV1 may be involved [124]. Subsequent studies
further supported this relationship and have found miR199a significantly inhibits CAV1 expression and function
[125]. Thus, when miR-199a is shown to have decreased
expression in SMZL cases, an increased expression
of CAV1 could be expected, which has shown to be
detrimental in other cancers [126–130]. Experimental
investigations into the relationship between CAV1 and
miR-199a may not only prove beneficial for understanding
its role in SMZL progression but could render fruitful for
deciphering other malignancies and diseases as well.

miR-485
The final miRNA of interest in this review is
miR-485. Arribas et al. demonstrated significant under
expression of miR-485 in SMZL samples [78]. The
decreased expression is consistent with many of the
previously published findings on miR-485, and it indicates
the miRNA exhibits primarily tumor suppressive properties
on SMZL pathogenesis. Increased expression of miR-485
has corresponded to enhanced treatment resistances in
tumor cells [140, 141], and increased expression has also
been shown to impact cell migration and invasion, colony
formation, cell viability, and mitochondrial functioning
in tumor cells, resulting in decreased cell viability [142,
143]. Additionally, decreased expression of miR-485

miR-376 cluster
An additional target of CAV1, the miR-376 cluster,
was also significantly under-expressed in SMZL compared
to non-tumoral controls [78]. The miR-376 family has not
been studied extensively, but it has been shown to act
with oncogenic properties in some malignancies while
displaying tumor suppressive functions in other cancers,
resulting in proposed utilization as a biomarker [131–
133]. The decrease in miR-376 expression in SMZL cases
indicates tumor suppressive properties, but the mechanistic
www.oncotarget.com
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